Haqq Christopher 4

4 · Elicio Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Elicio (ELTX) EVP/CMO Christopher Haqq Receives Equity Award

What Happened

Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics (ELTX), was granted equity awards on 2026-02-02: 25,400 restricted stock units (RSUs) and 50,900 option-based awards (reported as a derivative). Both awards were granted at $0.00 (no cash paid).

Key Details

Transaction date: 2026-02-02. Report filed 2026-02-03 (period of report 2026-02-02).
Grants: 25,400 RSUs (each RSU equals the right to one share) and 50,900 option-based derivative awards. Report shows acquisition code "A" (award/grant).
Price/Value: $0.00 reported for both grants (typical for equity compensation grants).
Vesting (per footnotes): RSUs vest 25% on Feb 2, 2027, then in annual installments over the next three years; the options vest 25% on Feb 2, 2027, with the remainder vesting monthly over the following three years.
Shares owned following the transaction: not specified in the filing.
Filing timeliness: filing date provided; no late filing flag noted.

Context

These awards are compensation grants that will convert to stock or become exercisable over multi-year vesting schedules if Haqq remains in service; they do not represent an immediate open-market purchase or sale.
The derivative entry reflects stock options (vesting/exercisable schedule) rather than an immediate exercise or sale.

Form 4

Period: 2026-02-02

See Remarks

Transactions

Award
Common Stock
[F1]
2026-02-02+25,400→ 57,381 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-02+50,900→ 50,900 total
Exercise: $8.10Exp: 2036-02-02→ Common Stock (50,900 underlying)

Footnotes (2)

[F1]Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.
[F2]The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Signature

/s/ Christopher Haqq|2026-02-03

1 file